Table 1 Patient characteristics

Entered

n = 54

Age median (years) (range)

46 years (range 25 – 73 y)

Estrogen receptor/progesterone receptor positive

23/15

HERcepTest+++/FISH+

51/3

primary metastatic disease

12 (22.2%)

Metastatic sites median (range)

3 (range 1–7 sites)

   Lung

22

   Liver

29

   Bones

30

   Lymph nodes

22

   Soft tissue

36

   Skin

11

   Brain

11

   Others

3

More than one metastatic site

48 (88.8%)

Adjuvant chemotherapy

31 (57.4%)

   Adjuvant docetaxel

13

   Adjuvant anthracyclines

19

Adjuvant endocrine therapy

15 (27.7%)

Palliative endocrine therapy

20 (37%)

1^st line combination

n = 54 pts

   Vinorelbine

35

   Capecitabine

2

   Gemcitabine

0

   Docetaxel

12

   Platinum derivatives

0

   Others

5

2^nd line combination

n = 54 pts

   Vinorelbine

15

   Capecitabine

11

   Gemcitabine

9

   Docetaxel

11

   Platinum derivatives

0

   Others

8

Beyond 2^nd line combination

n = 60 therapies

   Vinorelbine

6

   Capecitabine

14

   Gemcitabine

14

   Docetaxel

4

   Platinum derivatives

11

   Others

11